EXACT Sciences Corporation (EXAS)vsEli Lilly and Company (LLY)
EXAS
EXACT Sciences Corporation
$104.91
0.00%
HEALTHCARE · Cap: $20.03B
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1907% more annual revenue ($65.18B vs $3.25B). LLY leads profitability with a 31.7% profit margin vs -6.4%. LLY earns a higher WallStSmart Score of 78/100 (B+).
EXAS
Avoid32
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 23.1% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Trading at 8.3x book value
0.0% earnings growth
ROE of -8.7% — below average capital efficiency
Distress zone — elevated risk
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : EXAS
The strongest argument for EXAS centers on Revenue Growth. Revenue growth of 23.1% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : EXAS
The primary concerns for EXAS are Price/Book, EPS Growth, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
EXAS carries more volatility with a beta of 1.44 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 32/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
EXACT Sciences Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Exact Sciences Corporation offers cancer screening and diagnostic test products in the United States and internationally. The company is headquartered in Madison, Wisconsin.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?